Estudo randomizado | Dois estudos de fase 3 sobre baricitinibe para alopecia areata.
29 Mar, 2022 | 14:01hTwo Phase 3 Trials of Baricitinib for Alopecia Areata – New England Journal of Medicine
Comentário no Twitter
Alopecia areata is a distressing disorder of hair loss that is mediated partly by cytokines dependent on Janus kinases. The JAK1 and JAK2 inhibitor baricitinib reduced the extent of hair loss in two randomized trials over a period of 36 weeks. #AAD2022 https://t.co/oKKzGF7Q5S pic.twitter.com/gsgWJ1asZN
— NEJM (@NEJM) March 26, 2022